Results showed that CD19+/BTLA+/IL-10+ cells were overall significantly reduced in MS compared to HC (p < 0.05), with, the lowest percentages being observed in PPMS and SPMS patients (Fig. 5C,D). This evidence concerns the gene CD19 and myeloid sarcoma.